BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12931212)

  • 1. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
    Yazji S; Giles FJ; Tsimberidou AM; Estey EH; Kantarjian HM; O'Brien SA; Kurzrock R
    Leukemia; 2003 Nov; 17(11):2101-6. PubMed ID: 12931212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
    Stadler M; Germing U; Kliche KO; Josten KM; Kuse R; Hofmann WK; Schrezenmeier H; Novotny J; Anders O; Eimermacher H; Verbeek W; Kreipe HH; Heimpel H; Aul C; Ganser A
    Leukemia; 2004 Mar; 18(3):460-5. PubMed ID: 14712285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide for the treatment of patients with myelodysplastic syndromes.
    Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
    Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.
    Broliden PA; Dahl IM; Hast R; Johansson B; Juvonen E; Kjeldsen L; Porwit-MacDonald A; Sjoo M; Tangen JM; Uggla B; Oberg G; Hellstrom-Lindberg E
    Haematologica; 2006 May; 91(5):667-70. PubMed ID: 16670072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Outcome of immunosuppressive therapy for myelodysplastic syndromes: results of 12 cases from a single institution].
    Miyata A; Yasuda Y; Fujii S; Kikuchi T
    Rinsho Ketsueki; 2002 Oct; 43(10):911-7. PubMed ID: 12462026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Successful immunosuppressive therapy for a patient with hypoplastic myelodysplastic syndrome].
    Takanashi M; Kadono Y; Tabata Y; Hibi S
    Rinsho Ketsueki; 1999 Oct; 40(10):1093-9. PubMed ID: 10565227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
    Passweg JR; Giagounidis AA; Simcock M; Aul C; Dobbelstein C; Stadler M; Ossenkoppele G; Hofmann WK; Schilling K; Tichelli A; Ganser A
    J Clin Oncol; 2011 Jan; 29(3):303-9. PubMed ID: 21149672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
    Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunosuppressive treatment of the myelodysplastic syndrome].
    Larsen MS; Hasselbalch HC
    Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.
    Deeg HJ; Jiang PY; Holmberg LA; Scott B; Petersdorf EW; Appelbaum FR
    Leuk Res; 2004 Nov; 28(11):1177-80. PubMed ID: 15380342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
    Ghaddar HM; Stass SA; Pierce S; Estey EH
    Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Curative effects of cyclosporin A therapy upon myelodysplastic syndrome].
    Chen SC; Jiang B; Da WM; Gong M; Guan M
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(38):2711-5. PubMed ID: 17199984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cyclosporine A based therapy for myelodysplastic syndrome].
    Li ZL; Gong M; Xu SH; Huang FZ; Chen YR; Ma YG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):867-70. PubMed ID: 16277860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
    Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
    Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic studies in 32 patients with myelodysplastic syndrome: insights to specific chromosomal abnormalities and prognosis.
    Taniwaki M; Horiike S; Inazawa J; Nishida K; Misawa S; Takino T; Abe T
    Jpn J Clin Oncol; 1987 Jun; 17(2):141-50. PubMed ID: 3613138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithymocyte globulin for patients with myelodysplastic syndrome.
    Molldrem JJ; Caples M; Mavroudis D; Plante M; Young NS; Barrett AJ
    Br J Haematol; 1997 Dec; 99(3):699-705. PubMed ID: 9401087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia.
    Killick SB; Mufti G; Cavenagh JD; Mijovic A; Peacock JL; Gordon-Smith EC; Bowen DT; Marsh JC
    Br J Haematol; 2003 Feb; 120(4):679-84. PubMed ID: 12588356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.